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Proliferative response of human prostate tumour xenografts to surgical
trauma and the transurethral resection of the prostate controversy
AE Bogden, D LePage, S Zwicker, W Grant and M Silver
Biomeasure, 27 Maple Street, Mi/ford, MA 01757-3650, USA.
Summary Transurethral resection of the prostate (TURP) as an excisional procedure involving multiple
incisions into the prostate does not differentiate between palpably benign prostate tissue and microscopic foci
of well-differentiated adenocarcinoma. The impact of TURP on the progression of such 'latent' or 'incidental'
tumours unique to the prostate gland has been a focal point of a continuing controversy. In studies designed
to develop preclinical evidence that would lend support to, or detract from, either side of the TURP
controversy, surgical trauma-induced stimulation of in situ tumour growth was extended to include human
prostate tumour tissue PC-3, DU-145 and H-1579, albeit as xenografts in athymic nude males. A significant
proliferative response of prostate tumours implanted directly in, adjacent to, or distant from, a freshly induced
surgical wound, could be inhibited by a somatostatin analogue (Lanreotide) applied topically to the surgical
site. This preclinical model supports TURP as a risk factor for biopsy or therapeutic surgical intervention
procedures in benign prostatic hypertrophy (BPH), a risk factor that increases with the stage of disease in
undetected cancers. It also suggests a potential clinical benefit that might be derived by applying Lanreotide
directly to the surgically traumatised genitourinary area by simple irrigation of the urethra and bladder during
or shortly post TURP.
Keywords: prostatic trauma; proliferative response; somatostatin; lanreotide; transurethral resection of the
prostate controversy; inhibiting proliferative response
Although most patients with a palpably benign prostate who
undergo transurethral resections of the prostate (TURP) for
obstructive voiding symptoms have benign prostatic hyperp-
lasia (BHP), prostate cancer has been an incidental finding in
19% of patients during prostatectomy for BPH (Agatstein et
al., 1987) and in 10% of men with a clinical diagnosis of
BPH who underwent multiple directed and systematic
ultrasound-guided biopsies of the prostate (Coplen et al.,
1991). An astonishingly high prevalence of what pathologists
have interpreted as microscopic foci of well-differentiated
adenocarcinoma has been found at autopsy in serial sections
of prostate glands considered to be normal from men over
the age of 50. Every decade of ageing nearly doubles the
incidence of such tumours - from 10% in men in their 50s to
70% in men in their 80s (Scott et al., 1969; Sheldon et al.,
1980). Such a prevalence of 'latent' or 'incidental' tumours
appears to be unique to the prostate gland (Silverberg and
Lubera, 1989). The biological potential of focal low-grade,
incidentally discovered prostatic cancer (stage Al) has
generally been believed to be relatively innocuous, although
this view has been challenged in recent years by several
groups who have found a 16-27% rate of disease progres-
sion in patients followed for extended periods (Blute et al.,
1986; Epstein et al., 1986). The phenomenon of tumour cell
dissemination by surgical manipulation has been investigated
with various surgical procedures and tumour types and is
hardly a fresh topic. It has, however, become an important
concept for exploration with regard to prostatic carcinoma,
considering both the incidence of this particular tumour and
the frequency with which TURP has been performed for
obstructive symptoms. The actual impact of TURP on the
development of metastases, however, is not well defined.
McGowan (1980) has reported that the 5 year actuarial
disease-free survival of patients with clinical stage B and C
tumours treated by radiation therapy is significantly lower
for patients who have undergone prior TURP compared with
patients who have not undergone prior TURP. Further, it
has been speculated that the relatively poor prognosis of
patients with stage A2 prostatic tumours may be related to
tumour dissemination during TURP (Walsh, 1980). Whether
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the higher incidence of metastases seen in patients who had
TURP is due to the iatrogenic dissemination of malignant
cells (Hanks et al., 1983) or to the possibility that the
patients who were selected for TURP had a higher incidence
of clinically occult metastases before the procedure bears
upon the influences of the method of diagnosis (TURP vs
needle biopsy) on patient outcome, which is also controver-
sial (Hanks et al., 1986; Kuban et al., 1987; McGowan,
1988).
In a retrospective analysis of 225 patients with localised
adenocarcinoma of the prostate who were treated with
continuous-course external-beam radiation therapy, Amdur
et al. (1990) found that the 5 year rate of distant metastasis
was significantly greater in patients with stage C disease
when the biopsy was made by TURP, rather than by needle
biopsy, lending support to series that claim that diagnosis by
TURP reduces the likelihood of long-term relapse-free sur-
vival. The method of diagnosis was not prognostically impor-
tant, however, in patients with stage B disease. A mul-
tivariate Cox's hazard function analysis was performed by
Forman et al. (1986) on the prognostic variables selected
from 240 patients with localised carcinoma of the prostate,
who received external-beam radiotherapy, to analyse the
association between the method of biopsy and disease-free
survival. Median follow-up was 4 years. A multivariable
analysis demonstrated that 'method of biopsy', was the third
most powerful variable after serum acid phosphatase level
and modified Broder's grade in predicting disease-free sur-
vival. Patients who had TURP had an almost 2-fold higher
relative risk of disease progression than those who had needle
biopsy.
The recent report by Zagars et al. (1993), presenting the
results of a retrospective multivariate analysis of 874 cases of
prostate cancer treated between 1966 and 1988, is of special
relevance. The major goal of this study was to delineate
independently significant prognostic factors for prostate
cancer treated by external-beam radiation therapy, which
could serve as a basis for treatment selection. The disease
outcome and rate of survival was analysed with the propor-
tional hazards model for patients with stage A2 (104), stage
B (168) or stage C (602) prostate cancer with radiation
therapy as the only primary treatment. Factors that
independently correlated with metastases were high patho-
logical grade, TURP in stage C, elevated prostate acid phos-Proliferative response of prostate tumours to trauma
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phatase (PAP) levels and being 60 years of age or younger.
Although the adverse effect of TURP was evident in all
patients as a group, there was no correlation between TURP
and metastatic outcome in patients with stage A2/B disease.
In stage C, however, the adverse effect of TURP remained
significant even when stratified by grade. The results of mul-
tivariate analysis of factors independently correlated with
metastases revealed the following variables in order of
decreasing significance: MDA grade; in stage C, TURP vs no
TURP (P = 0.0003); normal vs elevated PAP; and age.
In multivariate analysis the factors significant for disease
relapse were also similar to those for metastatic failure.
TURP in stage C was the least significant predictor of any
relapse, but was second to grade as a predictor of metastatic
relapse.
TURP in stage C disease was highly correlated with poor
survival. In multivariate analysis only two factors correlated
with survival: MDA grade (1 vs 2 and 3 vs 4) and TURP in
stage C. None of the other variables approached significance
when these two were in the model.
The influence of TURP on metastatic disease has received
considerable attention and remains a controversial subject.
The majority of radiation studies find a highly significant
correlation between TURP in stage C disease and increased
subsequent metastases (Hanks et al., 1983; Forman et al.,
1986; McGowan 1987; Perez et al., 1989; Amdur et al., 1990)
but there are reports that such an association does not exist
(Anscher and Prosnitz, 1991) or that it can be totally
explained by the correlation between TURP and other fac-
tors, such as grade, which actually account for the heigh-
tened metastatic rates in patients undergoing TURP (Kuban
et al., 1987). However, the findings in these analyses leave
little doubt that TURP in stage C is highly correlated with
an increased metastatic risk and overall survival and that this
correlation cannot be explained away by any of the other
factors that have been analysed. A review of the literature
leaves little doubt that TURP, as a therapeutic modality for
the treatment of BPH, is an invasive surgical procedure that
may precede histological evidence of the presence or absence
of in situ cancer or metastasis and may, inadvertently, exacer-
bate an essentially latent disease. Our studies, therefore, have
addressed the following questions: Does surgical trauma
induce a proliferative surge in the growth of human prostatic
tumour tissue either adjacent to the trauma or more distant
from the trauma? Would the application of an anti-
secretagogue, such as the somatostatin analogue Lanreotide
(LAN), to the trauma site inhibit the proliferative surge?
Materials and methods
Prostate tumours
PC-3 human prostate adenocarcinoma was obtained from the
American Type Culture Collection, Rockville, MD, USA.
Originally established in in vitro cultures from a grade IV
prostatic adenocarcinoma, it was adapted to in vivo trans-
plantation in our laboratory.
DU-145 human prostate adenocarcinoma was also ob-
tained as in vitro culture from the American Type Culture
Collection. This cell line was isolated from a lesion in the
brain of a patient with widespread metastatic carcinoma of
the prostate. It was adapted to in vivo transplantation in our
laboratory.
H-1579 human prostate adenocarcinoma was established in
in vivo transplantation directly as a primary explant by one
of us. It has been maintained in cryopreservation in the
Breast Cancer Animal and Human Tumor Bank.
Animals
Immunodeficient athymic nude males (NCr-nu) were always
used as recipients of human prostate tumour xenografts, both
for serial transplantation and testing. All test animals, were
received from Harlan, Madison, Wisconsin, and housed in a
pathogen-free biocontainment facility. Tumour donor and
test animals were maintained ad libitum on an autoclaved,
taconic diet no 31, supplemented with multivitamins in the
drinking water and a wholewheat bread plus milk cake once
weekly. All procedures were performed in compliance with
the US-PHS regulations on humane use and care of
laboratory animals in a pathogen-free barrier facility main-
tained at Biomeasure.
Surgical trauma
A 12 mm-diameter, full thickness skin graft, was excised from
the left or right flank. The raw graft bed was then
traumatised by abrading with a burred needle. Abrasion was
accomplished by carefully, but firmly, drawing the burred
needle against the full length of the exposed subcutaneous
tissues four times and then again at right angles for four
times. Bleeding was minimal and the surgical wound was
immediately closed with Michel clamps. Animals were anaes-
thetized with i.p. administered 4% chloral hydrate.
Tumour xenograft implantations
Human prostate tumours were carried in serial transplanta-
tion by subcutaneous implantation of a 2-3 mm3 mince into
the right flank. To mimic the proximity of prostate tumour
to the surgical trauma, as occurs during TURP, a 2 mm3
mince of prostate tumour tissue was implanted directly into
the surgically traumatised area under the suture line. Such
tumour xenografts were implanted either within 1-2 h post
surgery or in the p.m. following the morning in which the
trauma had been induced.
To study the effect of surgical trauma on prostate tumours
distant to the surgical site, e.g. metastases, tumour tissue was
implanted s.c. in the flank opposite the trauma.
Lanreotide (LAN) treatment
Lanreotide (BIM-23014C, Somatuline) having the structure
[D-P-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2]acetate is a
long-acting octapeptide analogue of somatostatin (SRIF) a
neuroendocrine antisecretagogue (Heiman et al., 1987). To
enhance transdermal delivery it was administered at a con-
centration of 500fg 0.05 ml1 in either a 10% or 40%
dimethylsulphoxide (DMSO)/saline vehicle. Treatment con-
sisted of a 0.05 ml drop applied topically, b.i.d., to the
surgically treated area. LAN was then gently rubbed onto the
surgical area and around the wound clips for 1 min with a
latex-gloved finger. LAN is soluble at 2.5 mg ml-' saline for
s.c. administration.
Wound breaking strength
The effect of LAN on wound breaking strength in rats was
measured from surgical wounds 5 and 10 days post woun-
ding by Recherches & Expertises PB, Montreal, Canada.
LAN was administered topically to the wound area at a
concentration of 1.0 mg 100g.1' 50% DMSO/saline vehicle,
b.i.d., q.d., 1-10, eight rats per test group.
Evaluation
Tumours were measured three times weekly with Vernier
calipers and the length and width measurement in millimetres
for tumours of individual animals was recorded. Tumour
weight (mg) was calculated from tumour dimensions
(mm x mm), following the formula of a prolate ellipsoid:
L x W2
2
Where L is the longer of the two measurements and the first
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Results a
Response ofhuman prostate tumours implanted as xenografts 3000
directly into sites ofsurgically induced trauma
To determine the effect of surgically induced trauma on the
growth of prostate cancers under conditions that mimic the 0 2500
proximity of trauma to malignant prostate tissue as occurring u
during TURP, the three human prostate tumours PC-3, DU-
145 and H-1579 were implanted as xenografts directly into c 2000
sites of surgically induced trauma. As controls, the same size E
of tumour inocula were implanted s.c. into athymic males C
that were not surgically treated. 1500
Figure 1 illustrates the accelerated growth of human pros-
tate tumour xenografts in surgically traumatised mice as o
compared with growth of each tumour in non-surgically E
1000 treated animals. All prostate tumours implanted directly into a)
the trauma site grew at a significantly faster rate than the L
same size inocula implanted in non-traumatised animals: H- ±
1579 implanted directly into surgically traumatised tissue was 500
over nine times greater in size by day 30 post implantation
(P<0.001); DU-145 was over seven times greater in size by
day 26 post implantation (P<0.01); and, the PC-3 was 0
P= 0.004
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almost four times greater in size by day 26 post implantation b 1 2 3
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traumatised animals.
Response ofhuman prostate tumour xenografts distantfrom
the site ofsurgical trauma
It is obvious that surgical trauma induces a significant pro-
C 1500
liferative surge when malignant prostate tissue is implanted
directly into the site of trauma. The following study add-
resses the question, does surgical trauma effect prostate E
tumour tissue implanted distant from the site of trauma?
To demonstrate the effect of surgical trauma on prostate
tumour distant from the trauma site, animals were treated ¢ 1000
surgically in the morning. Human prostate tumour tissue, o
H-1579, PC-3 or DU-145, was implanted into one group E
directly into the trauma site under the wound clips, s.c. in the
flank opposite from the trauma site in another group and, as
a normal control, the same size inocula were implanted in
non-traumatised animals. Tumour implantations were acc-
omplished within 2-3 h after surgery.
Figure 2a compares the proliferative response of H-1579
implanted directly into the traumatised site (group 2) and 1 2 3
distally (opposite flank) from the trauma (group 3). Tumour C
growth in both sites is compared with tumour growth in 2000
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Figure 2 Proximity of prostate tumours to a surgical lesion and
Figure I The proliferative response of human prostate tumours the proliferative response to trauma. Human prostate tumours
H-1579, DU-145 and PC-3 to surgical trauma. Growth of tumour H-1579 (a), PC-3 (b) and DU-145 (c), were implanted s.c. in
xenografts implanted intralesionally in surgically traumatised non-traumatised animals (group 1; ), intralesionally (group
animals ( ELZ) is compared with growth of similar tumour 2; ) and s.c. distally (opposite flank) from the lesion (group 3;
inocula implanted s.c. in non-traumatised animals ( _ ). ITh), in traumatised animals.
P= 0.014
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Figure 3 Inhibiting the trauma-induced accelerated growth of
human prostate tumour xenografts by treating the surgical lesion
topically with Lanreotide. PC-3 tumour xenografts were im-
planted s.c. in non-traumatised animals, (group 1; ) and
intralesionally in traumatised animals (group 5; 1111), as un-
treated controls. Group 3 ( 1 ) and group 4 ( 1 ) animals
were implanted s.c. in the flank opposite (distant) from the
surgical lesion in traumatised animals and had their respective
trauma sites treated topically with the 10% DMSO/saline vehicle
(group 3) or Lanreotide (group 4).
non-traumatised animals (group 1). By day 30 post implanta-
tion tumour sizes were significantly greater in the surgically
traumatised animals whether the tumour had been implanted
into the site of trauma (P = 0.004) or in the site away from
the trauma (P = 0.014). Importantly, proximity of malignant
tissue to the trauma increased the proliferative response over
that of malignant tissue implanted distant to the trauma by a
factor of 3 (P<0.05).
Figure 2b compares the proliferative response of PC-3 and
Figure 2c compares the proliferative response of DU-145
implanted into the traumatised area (group 2) and distally
from the trauma (group 3) as well as in non-traumatised
(group 1) animals. By day 26 post implantation both
tumours exhibited significantly greater growth in traumatised
compared with non-traumatised animals whether implanted
into the site of trauma (DU-145, P = 0.001; PC-3, P = 0.002)
or the site away from the trauma (DU-145, P = 0.06; PC-3,
P = 0.03). In all instances proximity of the malignant tissue
to the surgically treated site resulted in a significantly in-
creased rate of tumour growth.
Inhibiting the surgical trauma-inducedproliferative surge of
human prostate tumour xenografts
In previous studies (Bogden et al., 1993) with a number of
transplantable human and animal tumours we have been able
to confirm a long-recognised phenomenon, the surgical
trauma-induced proliferative surge of in situ malignant tis-
sues. Of particular significance in these early studies was our
ability to inhibit the proliferative surge by topical application
of LAN to the surgical site.
Expanding these observations to include human prostate
tumours (Figure 3), PC-3 tumour xenografts were implanted
s.c. into non-traumatised (group 1) and into surgically
traumatised athymic mice in the flank opposite the trauma
(groups 3, 4 5). LAN, at 500 jig in a 10% DMSO/saline
vehicle, as well as the vehicle per se, were administered b.i.d.
on days 1- 15 topically only to the trauma site. By day 15
post implantation tumour xenografts implanted in surgically
traumatised animals (group 5) had significantly increased in
size (P<0.001). Treatment of the trauma site with the 10%
DMSO/saline vehicle (group 3) significantly (P<0.01)
inhibited tumour growth when compared with the trauma
only control (group 5). Treatment of the trauma site with
LAN in the 10% DMSO/saline vehicle (group 4) significantly
inhibited tumour growth when compared with the trauma
only control (P<0.001) and further inhibited tumour growth
significantly (P = 0.01) better than treatment with the vehicle
alone (group 3). Treatment of the trauma site over the 15
day period with LAN had completely inhibited the trauma-
induced proliferative surge maintaining tumour growth at the
level of the non-traumatised shelf control (group 1).
Table I summarises the results obtained with different
treatment protocols designed to demonstrate the inhibitory
effect on prostate tumour growth by treating the trauma site
with LAN. In assay BL94-610 and BL93-605, animals were
implanted with the appropriate prostate tumour s.c., right
flank, in the morning of day 0. In the evening of the same
day surgical trauma was induced in the left flank. Within
2-3 h post traumatisation, LAN at a concentration of 500 tg
0.05 ml1' 10% DMSO/saline was applied topically to the
wound area with gentle rubbing for 1 min. There were no
additional treatments. On day 27 post implantation, the H-
1579 human prostate tumour still exhibited significant
(P<0.01) inhibition with a 66% test-control ratio (T/C). By
day 15 post implantation, the PC-3 human prostate tumour
was also inhibited with a 57% T/C, which was not statis-
tically significant.
In assay BL93-510 animals were surgically traumatised on
the left flank in the morning of day 0, the PC-3 tumour
implanted in the right flank in the evening of day 0, and
treatment of the traumatised area was initiated on day 1.
LAN was administered topically at a concentration of 500 ,ug
0.05 ml-' in a 40% DMSO/saline vehicle, b.i.d., on days
1-25. PC-3 exhibited a slight inhibitory effect (74% T/C)
that was not statistically significant in animals with wound
areas treated only with the 40% DMSO/saline vehicle. How-
ever, in animals treated similarly with LAN in the same
vehicle inhibition of PC-3 was statistically significant
(P = 0.017), inducing a 65% T/C.
In assay BL93-593 the left flanks ofanimals were surgically
traumatised in the morning of day 0. Within 2 h of
traumatisation animals were implanted s.c. in the opposite or
right flank with xenografts of the DU-145 prostate tumour.
Treatment of the trauma site with topically applied LAN in a
10% DMSO/saline vehicle was initiated in the morning of
day 0 and continued on a twice-daily regimen for days 0-26.
Treatment of the trauma site with the 10% DMSO/saline
vehicle alone had a slight inhibitory effect (59% T/C) that
was not statistically significant. Treatment of the trauma site
with LAN, however, induced a 20% T/C that was significant
at the P<0.05 level).
Effect ofLAN on woundbreaking strength
An early inhibitory effect (day 5 after surgical wounding) was
observed, which was reversed on day 10 suggesting, that
when applied topically to a wound area, LAN slightly delays
the initiation of collagen synthesis at the wound site (Table
II). This effect coincides with the time-defined window of
2-3 days duration post surgery in which trauma-induced
factors stimulate a proliferative surge of distant in situ
tumours.
Discussion
Accelerated growth of residual tumour and outgrowth of
existing metastases following surgical excision of a primary
tumour was noted, at least, as far back as the time of Ehrlich
(1908). Enhanced growth of metastases following partial
excision of implanted tumours in mice was first reported by
avvProliferative response of prostate tumours to trauma
AE Bogden etal
Table I Inhibition ofthetrauma-induced proliferative surgebytreatmentofthetraumasitewith
Lanreotide
Assay no. Tumour/treatment Tumour weight (mg)a T/Cb
BL94-610 H-1579 (day 27)
Trauma control 850 ± 69
Trauma, LAN 500fig topical to 560 ± 68 P<0.01 66
trauma, day 0 only
BL94-605 PC-3 (day 15)
Trauma control 372 ± 108
Trauma, LAN 500jig topical to 213 ± 27 NS 57
trauma, day 0 only
BL93-510 PC-3 (day 25)
Trauma control 1008 ± 115
Trauma, 40% DMSO/saline topical 751 ± 100 NS 74
to trauma, b.i.d., days 1-25
Trauma, LAN, 500fig topical to 659 ± 67 P 0.017 65
trauma, b.i.d., days 1-25
BL93-593 DU-145 (day 27)
Trauma control 530 ± 175
Trauma, 10% DMSO/saline topical 312 ± 99 NS 59
to trauma, b.i.d., days 0-26
Trauma, LAN 500jig topical to 104 41 P<0.05 20
trauma, b.i.d., days 0-26
are means ± s.e.m. b Tumour weight test/tumour weight control x 100. NS, not
a Values
significant.
Table II Theeffect oftopically applied Lanreotide on wound breaking
strength
Wound breaking strength
Treatment Ncm-' (post trauma)
Day 5 Day 10
Control, 50% DMSO/saline 1.57 ± 0.05 4.79 ± 0.27
vehicle, b.i.d., topical
Lanreotide, 1.0 mg, in 50% 1.31 ± 0.OSa 4.79 ± 0.32
DMSO/saline vehicle, b.i.d.,
topical
Data reported as means ± s.e.m. on eight rats per group.
aSignificantly different from control (P<0.01) on day 5 only.
Marie and Clunet (1910) and by Tyzzer (1913). Of particular
relevance to our studies was the relatively more recent obser-
vation by Simpson-Herren et al. (1976). A surgical procedure
that was designed to simulate tumour excision but left both
the primary tumour and its spontaneous metastases undis-
turbed resulted in an increase in the thymidine index of
Lewis lung pulmonary metastases, and a decrease in life-
span. In addition, however, the thymidine index of the
primary tumours was also increased. Fisher et al. (1989)
evaluated the effect of removal of a primary tumour on the
kinetics of cells in a metastasis using six histologically
different tumours. They found an increase in the labelling
index of distant tumour foci (metastases) associated with the
removal of each of the tumour types. Serum obtained from
mice following removal of a tumour, when transferred to a
recipient with the same type of tumour as in the donor,
resulted in an increase in the labelling index of the tumour.
Such adverse effects related to metastatic growth, as either
direct or indirect effects of a surgical procedure, trauma,
incisional biopsy or stress, have been reported in both man
and experimental animals emphasising the importance of
investigating the effects of surgery on in situ residual prostate
cancer. (Schatten, 1958, Romsdahl, 1964, Riggins and Ket-
cham, 1965; Rudenstam, 1968; Simpson-Herren et al., 1974).
Prostatectomy for benign disease is a misnomer (Schwartz et
al., 1986). Regardless of the type of prostatectomy performed
for benign obstructive disease (suprapubic, retropubic,
perineal or transurethral), the prostate is not removed. A
variable but substantial thickness of glandular prostatic tissue
remains after removal of an adenomatous enlargement of the
periurethral glands (Smith and Woodruff 1950; Page, 1980).
Cancer can and does develop in the remaining prostatic
tissues.
Of particular importance, therefore, is the pathological
evidence of clinically occult cancer that is found in 10-20%
of men undergoing surgery for BPH (Denton et al., 1965;
Coplen et al., 1991). Stage A carcinoma of the prostate has
been defined as cancer found at autopsy incidentally and in
pathological sections of resected glands believed pre-
operatively to have been benign. One might assume that the
risk of promoting stage TI cancer growth and latent cancer
following TURP for BPH is low, because these small lesions
appear to contain a high proportion of low-grade cancers
that have not achieved the molecular capacity to benefit from
local growth factors nor have the molecular mechanisms
necessary to constitute a metastatic phenotype (McNeal
1993). This assumption is supported by the finding that in a
population of 198 BPH patients subjected to TURP 10 non-
palpable prostate cancers were detected at surgery, one
patient having a high-grade and nine having a low-grade
cancer (Hammarsten et al., 1994). However, in the same
study three of ten patients having undergone TURP with
stage Ti cancer developed clinical prostatic cancers in a 10
year follow-up period. This progression rate in stage Ti
cancers is confirmed by findings in other studies that approx-
imately 25% of patients with prostate cancer unexpectedly
detected at operation for BPH had disease progression dur-
ing an average of 10 years of follow-up (Lowe and Listrom
1988; Johansson et al., 1992). Although the incidence of
clinical prostate cancer resulting from progression of stage
Ti lesions may appear low, the burden on the health care
system is substantial since more than one million men
undergo TURP every year (Hammarsten et al., 1994).
Our studies have reconfirmed and extended the pheno-
menon of a surgical trauma-induced proliferative surge to
include human prostate tumour tissue, albeit as xenografts
implanted to the immunodeficient athymic nude mouse. Sur-
gical trauma clearly stimulated the growth of human prostate
tumours implanted either adjacent to or directly in the
trauma site, as well as, distant from the site. A proliferative
response of malignant tissues distant (opposite flank) from
the trauma suggests blood-borne growth factors. Inhibition
of the proliferative response by treating the surgical site with
a somatostatin analogue (Lanreotide, a growth factor
antisecretagogue) suggests that the proliferative response of
malignant tissue is a response to positive growth factors or
their inducers released at the site of trauma for repair of
normal tissue and may effect systemic metastases.
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Although optimal therapeutic regimens have not been
defined in these studies, feasibility of inhibiting the tumour-
stimulatory effects of surgical trauma has been demonstrated.
A single topical application of Lanreotide to the trauma site,
within 2-3 h of surgery, significantly inhibited stimulation of
tumour growth. Ancillary studies (unpublished data) in
which malignant tissue was implanted on the day of
traumatisation and on 4 consecutive days thereafter, revealed
a time-defined window of only 2-3 days duration after
surgery in which trauma-induced factors stimulated tumour
growth systemically. Such results suggest the clinical prac-
ticability of applying LAN, during or shortly post TURP,
directly to the surgically traumatised area by simple irriga-
tion of the urethra and bladder.
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